Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-Analysis

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Lu, Beibei ^a   Kumar, Ambuj ^b   Castellsagué, Xavier ^c   Giuliano, Anna R ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD DISEASE; BREAST DISEASE; BRONCHOSPASM; CANCER GRADING; CONNECTIVE TISSUE DISEASE; CROSS PROTECTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; GASTROENTERITIS; GASTROINTESTINAL DISEASE; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HYPERTENSION; IMMUNOPATHOLOGY; INFECTION RISK; INJECTION SITE PAIN; INTENTION TO TREAT ANALYSIS; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MEDIASTINUM DISEASE; MENTAL DISEASE; META ANALYSIS; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PERSISTENT INFECTION; PREGNANCY OUTCOME; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; SIDE EFFECT; SKIN DISEASE; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; THORAX DISEASE; UROGENITAL TRACT DISEASE; UTERINE CERVIX DISEASE; VASCULAR DISEASE; VIRUS LIKE AGENT; DRUG TOXICITY; GENETICS; ISOLATION AND PURIFICATION; PAPILLOMA VIRUS; PHYSIOLOGY; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UTERINE CERVIX TUMOR; VIROLOGY;

ADOLESCENT; ADULT; DRUG TOXICITY; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 78651250137     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-13     Document Type: Article

References (33)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F, 10451482.
2. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121(3):621-632. 10.1002/ijc.22527, 17405118.
3. La Torre G, de Waure C, Chiaradia G, Mannocci A, Ricciardi W. HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis. Vaccine 2007, 25(50):8352-8358. 10.1016/j.vaccine.2007.09.027, 17996990.
4. Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007, 177(5):469-479. 1950172, 17671238.
5. La Torre G, Chiaradia G, de Waure C, Nicolotti N, Monteduro A, Ricciardi W. Report HTA del vaccino quadrivalente anti-HPV Gardasil (HTA report on quadrivalent HPV vaccine). Ital J Public Health 2009, 6(2.s2):16-24.
6. La Torre G, de Waure C, Chiaradia G, Mannocci A, Capri S, Ricciardi W. The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy. Vaccine 2010, 28(19):3379-3384. 10.1016/j.vaccine.2010.02.080, 20197141.
7. Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans/World Health Organization, International Agency for Research on Cancer 2007, 90:1-636.
8. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364(9447):1757-1765. 10.1016/S0140-6736(04)17398-4, 15541448.
9. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367(9518):1247-1255. 10.1016/S0140-6736(06)68439-0, 16631880.
10. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560. 10.1136/bmj.327.7414.557, 192859, 12958120.
11. Begg CB, Mazumdar M. Operating Characteristics of a Rank Correlation Test for Publication Bias. Biometrics 1994, 50(4):1088-1101. 10.2307/2533446, 7786990.
12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj 1997, 315(7109):629-634. 2127453, 9310563.
13. The Cochrane Collaboration Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. 2009, The Cochrane Collaboration.
14. Review Manager (RevMan). 2008, Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 5.0.
15. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535. 10.1136/bmj.b2535, 2714657, 19622551.
16. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314. 10.1016/S0140-6736(09)61248-4, 19586656.
17. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(19):1928-1943. 10.1056/NEJMoa061760, 17494926.
18. Munoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009, 373(9679):1949-1957. 10.1016/S0140-6736(09)60691-7, 19493565.
19. Collins S, Mazloomzadeh S, Winter H, Blomfield P, Bailey A, Young LS, Woodman CB. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 2002, 109(1):96-98. 10.1111/j.1471-0528.2002.01053.x, 11845815.
20. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003, 157(3):218-226. 10.1093/aje/kwf180, 12543621.
21. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007, 298(7):743-753. 10.1001/jama.298.7.743, 17699008.
22. Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009, 5(10). 10.4161/hv.5.10.9515, 19855170.
23. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Hoye J, Steinwall M, Riis-Johannessen G, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95(11):1459-1466. 10.1038/sj.bjc.6603469, 2360730, 17117182.
24. Rowhani-Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, Hawes SE, Weiss NS, Koutsky LA. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 2009, 27(41):5612-5619. 10.1016/j.vaccine.2009.07.027, 2749988, 19647066.
25. Future II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(19):1915-1927. 10.1056/NEJMoa061741, 17494925, Future II Study Group.
26. Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, Saah A, Marino D, Ryan D, Radley D, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009, 114(6):1179-1188. 10.1097/AOG.0b013e3181c2ca21, 19935017.
27. National Vital Statistics Reports. 2009, 58:15. Atlanta: Centers for Disease Control and Prevention; National Center for Health Statistics.
28. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347(21):1645-1651. 10.1056/NEJMoa020586, 12444178.
29. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006, 107(1):18-27. 10.1097/01.AOG.0000192397.41191.fb, 16394035.
30. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6(5):271-278. 10.1016/S1470-2045(05)70101-7, 15863374.
31. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. The Journal of infectious diseases 2009, 199(7):926-935. 10.1086/597307, 19236279.
32. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. The Journal of infectious diseases 2009, 199(7):936-944. 10.1086/597309, 19236277.
33. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369(9580):2161-2170. 10.1016/S0140-6736(07)60946-5, 17602732.